Source: https://patents.google.com/patent/AU2013200007B2/en
Timestamp: 2019-07-17 23:08:54
Document Index: 453974859

Matched Legal Cases: ['art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12', 'art 12']

AU2013200007B2 - Contact assessment based on phase measurement - Google Patents
AU2013200007B2
AU2013200007B2 AU2013200007A AU2013200007A AU2013200007B2 AU 2013200007 B2 AU2013200007 B2 AU 2013200007B2 AU 2013200007 A AU2013200007 A AU 2013200007A AU 2013200007 A AU2013200007 A AU 2013200007A AU 2013200007 B2 AU2013200007 B2 AU 2013200007B2
AU2013200007A
AU2013200007A1 (en
2013-01-02 Application filed by Biosense Webster Israel Ltd filed Critical Biosense Webster Israel Ltd
2013-07-18 Publication of AU2013200007A1 publication Critical patent/AU2013200007A1/en
2016-03-03 Publication of AU2013200007B2 publication Critical patent/AU2013200007B2/en
Methods and systems achieve tissue ablation, which is carried out by inserting a probe having an ablation electrode into a body of a living subject, and while the ablation electrode is in a non-contacting relationship to a target tissue, making a pre-contact determination of a phase of an electrical current passing between the ablation electrode and another electrode. The ablation electrode is placed in contact with the target tissue, and while the ablation electrode is in the contacting relationship, a dosage of energy is applied via the ablation electrode to the target tissue for ablation thereof. Iterative intra-operative determinations of the phase of the electrical current are made. When one of the intra operative determinations satisfies a termination criterion, the energy application is terminated. 1 39 3-2 REF PRE- 43 47(
AUSTRALIA Patents Act 1990 ORIGINAL COMPLETE SPECIFICATION INVENTION TITLE: CONTACT ASSESSMENT BASED ON PHASE MEASUREMENT The following statement is a full description of this invention, including the best method of performing it known to us:- CONTACT ASSESSMENT BASED ON PHASE MEASUREMENT FIELD OF THE INVENTION [0001] This invention relates to tissue ablation systems. More particularly, this invention relates to monitoring of contact between an invasive probe and tissue within the body. DESCRIPTION OF THE RELATED ART [0002] Cardiac arrhythmias, such as atrial fibrillation, occur when regions of cardiac tissue abnormally conduct electric signals to adjacent tissue, thereby disrupting the normal cardiac cycle and causing asynchronous rhythm. [00031 Procedures for treating arrhythmia include surgically disrupting the origin of the signals causing the arrhythmia, as well as disrupting the conducting pathway for such signals. By selectively ablating cardiac tissue by application of energy via a catheter, it is sometimes possible to cease or modify the propagation of unwanted electrical signals from one portion of the heart to another. The ablation process destroys the unwanted electrical pathways by formation of non-conducting lesions. [0004] Verification of physical electrode contact with the target tissue is important for controlling the delivery of ablation energy. Attempts in the art to verify electrode contact with the tissue have been extensive, and various techniques have been suggested. For example, U.S. Patent No. 6,695,808 describes apparatus for treating a selected patient tissue or organ region. A probe has a contact surface that may be urged against the region, thereby creating contact pressure. A pressure transducer measures the contact pressure. This arrangement is said to meet the needs of procedures in which a medical instrument must be placed in firm but not excessive contact with an anatomical surface, by providing information to the user of the instrument that is indicative of the existence and magnitude of the contact force.
2 [0005] As another example, U.S. U.S. Patent No. 6,241,724 describes methods for creating lesions in body tissue using segmented electrode assemblies. In one embodiment, an electrode assembly on a catheter carries pressure transducers, which sense contact with tissue and convey signals to a pressure contact module. The module identifies the electrode elements that are associated with the pressure transducer signals and directs an energy generator to convey RF energy to these elements, and not to other elements that are in contact only with blood. [0006] A further example is presented in U.S. Patent No. 6,915,149. This patent describes a method for mapping a heart using a catheter having a tip electrode for measuring local electrical activity. In order to avoid artifacts that may arise from poor tip contact with the tissue, the contact pressure between the tip and the tissue is measured using a pressure sensor to ensure stable contact. [0007] U.S. Patent Application Publication 2007/0100332 describes systems and methods for assessing electrode-tissue contact for tissue ablation. An electro-mechanical sensor within the catheter shaft generates electrical signals corresponding to the amount of movement of the electrode within a distal portion of the catheter shaft. An output device receives the electrical signals for assessing a level of contact between the electrode and a tissue. [0008] U.S. Patent No. 7,306,593, issued to Keidar et al., describes a method for ablating tissue in an organ by contacting a probe inside the body with the tissue to be ablated, and measuring one or more local parameters at the position using the probe prior to ablating the tissue. A map of the organ is displayed, showing, based on the one or more local parameters, a predicted extent of ablation of the tissue to be achieved for a given dosage of energy applied at the position using the probe. The given dosage of energy is applied to ablate the tissue using the probe, and an actual extent of the ablation at the position is measured using the probe subsequent to ablating the tissue. The measured actual extent of the ablation is displayed on the map for comparison with the predicted extent. [0009] Impedance-based methods for assessing catheter-tissue contact that are known in the art typically rely on measurement of the magnitude of the impedance 3 between an electrode on the catheter and a body-surface electrode. When the magnitude is below some threshold, the electrode is considered to be in contact with the tissue. This sort of binary contact indication may be unreliable, however, and is sensitive to changes in the impedance between the body-surface electrode and the skin. [0010] U.S. Patent Application Publication Nos. 2008/0288038 and 2008/0275465, all by Sauarav et al., which are herein incorporated by reference, describe an electrode catheter system may comprise an electrode adapted to apply electric energy. A measurement circuit adapted to measure impedance may be implemented between the electrode and ground as the electrode approaches a target tissue. A processor or processing units may be implemented to determine a contact condition for the target tissue based at least in part on reactance of the impedance measured by the measurement circuit. In another embodiment, the contact condition may be based on the phase angle of the impedance. [001 Oa] US 2010/0069921 describes a method for assessing lesion formation in tissue. WO 2009/065140 described an ablation system for providing feedback on lesion formation in real-time. US 2002/0068931 describes an a apparatus for ablating organic material and a procedure to generate indicia of teal time characteristics of the ablation site. BACKGROUND OF THE INVENTION [0011] There is provided according to embodiments of the invention a method of ablation, which is carried out by inserting a probe having an ablation electrode into a body of a living subject, and while the ablation electrode is in a non-contacting relationship to a target tissue, making a pre-contact determination of a phase of an electrical current passing between the ablation electrode and another electrode. The method is further carried out by urging the ablation electrode into a contacting relationship with the target tissue, and while the ablation electrode is in the contacting relationship applying a dosage of energy via the ablation electrode to the target tissue for ablation thereof, iteratively making intra-operative determinations of the phase of the electrical current. The method is further carried out by establishing that one of the intra-operative determinations satisfies a termination criterion 3a for completion of the ablation, and responsively thereto, terminating the energy application. [0012] One aspect of the method includes displaying a visual indication of the intra-operative determinations of the phase of the electrical current. The visual indication 4 may include a progress display of the ablation with respect to an intended lesion in the target tissue. [0013] According to yet another aspect of the method, the termination 5 criterion includes a difference between one of the intra-operative determinations and the pre-contact determinaion that is less than a predetermined value, [0014] According to still another aspect of the method, the termination 10 critaeon includes a failure of one of theintra-operative determinations to vary from a preceding one of the intra-operative determinations by more than a threshold value. [0015] According to an additional aspect of the method, making the pre 15 contact determination and the intra-operative determinations comprise measuring a phase of an impedance between an electrode on the probe and a body-surface electrode. [0016] According to one aspect of the method, making the pre-contact 20 determination and the intra-operative determinations includes making a comparison with respective phases of a reference waveform taken from a reference electrode that is spaced apart from the target tissue. [0017] in a further aspect of the method, making intra-operative 25 determinations is performed every 2-5 seconds. [0018 In yet another aspect of the method, making intra-operative determinations and applying a dosage of energy are performed concurrently. 30 [0019] According to stil another aspect of the method, making a pre contact determination is performed at a power of ies than 10 mildwatts 4a [00201 According to an additonal aspect of the method making intra operative determinations is performed at a power of 5- 50 watts. [00211 in accordance with the present invention, therefore, there is 5 provided an ablation apparatus, induding; a flexible catheter adapted for insertion into a heart of a living subject and having a distally disposed ablation electrode to be brought into contact wAh a target tissue in the heart; an abator, which applies a dosage of energy to the target tissue so as to ablate the target tissue; an impedance measuring subsystem, induding a 10 body surface electrode to be attached to the subject, having first circuitry for passing an electrical current between the body surface electrode and the ablation electrode and second circuitry for determining a phase of the electrical current; third circuitry for making iterative intra-operative determinations of phase shifts of the electrical current; and a monitor linked 15 to the lhid circuitry, which is operative to display aisual indication of the phase shifts during operation of the ablator wherein the abiator and the third circuitry are configured concurrently to apply the dosage of energy and make the intramoperative determinations, respectively, 5 BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS [0022] For a better understanding of the present invention, reference is made to the detailed description of the invention, by way of example, which is to be read in conjunc tion with the following drawings, wherein like elements are given like reference numerals, and wherein: [0023] Fig. 1 is a pictorial illustration of a system for performing ablative procedures on a heart of a living subject, which is constructed and operative in accordance with an embodiment of the invention; [0024] Fig. 2 is a composite drawing illustrating phase relationships of currents passing through an electrode of the catheter as it moves into contact with heart tissue in accordance with an embodiment of the invention; and [0025] Fig. 3 is a flow chart of a method of tissue ablation in accordance with an embodiment of the invention. DETAILED DESCRIPTION OF THE INVENTION [0026] In the following description, numerous specific details are set forth in order to provide a thorough understanding of the various principles of the present invention. It will be apparent to one skilled in the art, however, that not all these details are necessarily always needed for practicing the present invention. In this instance, well-known circuits, control logic, and the details of computer program instructions for conventional algorithms and processes have not been shown in detail in order not to obscure the general concepts unnecessarily. [0027] Aspects of the present invention may be embodied in software programming code, which is typically maintained in permanent storage, such as a computer readable medium. In a client/server environment, such software programming code may be stored on a client or a server. The software programming code may be embodied on any of a variety of known non-transitory media for use with a data processing system, such as a diskette, hard drive, electronic media or CD-ROM. The code may be distributed on such 6 media, or may be distributed to users from the memory or storage of one computer system over a network of some type to storage devices on other computer systems for use by users of such other systems. [0028] Turning now to the drawings, reference is initially made to Fig. 1, which is a pictorial illustration of a system 10 for performing ablative procedures on a heart 12 of a living subject, which is constructed and operative in accordance with a disclosed embodiment of the invention. The system comprises a catheter 14, which is percutaneously inserted by an operator 16 through the patient's vascular system into a chamber or vascular structure of the heart 12. The operator 16, who is typically a physician, brings the catheter's distal tip 18 into contact with the heart wall at an ablation target site. Optionally, Electrical activation maps may then be prepared, according to the methods disclosed in U.S. Patent Nos. 6,226,542, and 6,301,496, and in commonly assigned U.S. Patent No. 6,892,091. One commercial product embodying elements of the system 10 is available as the CARTO@ 3 System, available from Biosense Webster, Inc., 3333 Diamond Canyon Road, Diamond Bar, CA 91765. [0029] Areas determined to be abnormal, for example by evaluation of the electrical activation maps, can be ablated by application of thermal energy, e.g., by passage of radiofrequency electrical current through wires in the catheter to one or more electrodes at the distal tip 18, which apply the radiofrequency energy to the myocardium. The energy is absorbed in the tissue, heating it to a point (typically about 50 0 C) at which it permanently loses its electrical excitability. When successful, this procedure creates non conducting lesions in the cardiac tissue, which disrupt the abnormal electrical pathway causing the arrhythmia. The principles of the invention can be applied to different heart chambers to treat many different cardiac arrhythmias. [0030] The catheter 14 typically comprises a handle 20, having suitable controls on the handle to enable the operator 16 to steer, position and orient the distal end of the catheter as desired for the ablation. To aid the operator 16, the distal portion of the catheter 14 contains position sensors (not shown) that provide signals to a positioning processor 22, located in a console 24.
7 [0031] Ablation energy and electrical signals can be conveyed to and from the heart 12 through one or more ablation electrodes 32 located at or near the distal tip 18 via cable 34 to the console 24. Pacing signals and other control signals may be conveyed from the console 24 through the cable 34 and the electrodes 32 to the heart 12. Sensing electrodes 33, also connected to the console 24 are disposed between the ablation electrodes 32 and have connections to the cable 34. [0032] Wire connections 35 link the console 24 with body surface electrodes 30 and other components of a positioning sub-system. The electrodes 32 and the body surface electrodes 30 may be used to measure tissue impedance at the ablation site as taught in U.S. Patent No. 7,536,218, issued to Govari et al. A temperature sensor (not shown), typically a thermocouple or thermistor, may be mounted on or near each of the electrodes 32. [0033] The console 24 typically contains one or more ablation power generators 25. The catheter 14 may be adapted to conduct ablative energy to the heart using any known ablation technique, e.g., radiofrequency energy, ultrasound energy, and laser-produced light energy. Such methods are disclosed in commonly assigned U.S. Patent Nos. 6,814,733, 6,997,924, and 7,156,816. [0034] The positioning processor 22 is an element of a positioning system 26 of the system 10 that measures location and orientation coordinates of the catheter 14. [0035] In one embodiment, the positioning system 26 comprises a magnetic position tracking arrangement that determines the position and orientation of the catheter 14 by generating magnetic fields in a predefined working volume its vicinity and sensing these fields at the catheter using field generating coils 28 and may include impedance measurement, as taught, for example in U.S. Patent Application Publication No. 2007/0060832. The positioning system 26 may be enhanced by position measurements using the impedance measurements described in the above-noted U.S. Patent No. 7,536,218.
8 [0036] As noted above, the catheter 14 is coupled to the console 24, which enables the operator 16 to observe and regulate the functions of the catheter 14. Console 24 includes a processor, preferably a computer with appropriate signal processing circuits. The processor is coupled to drive a monitor 29. The signal processing circuits typically receive, amplify, filter and digitize signals from the catheter 14, including signals generated by the above-noted sensors and a plurality of location sensing electrodes (not shown) located distally in the catheter 14. The digitized signals are received and used by the console 24 and the positioning system 26 to compute the position and orientation of the catheter 14 and to analyze the electrical signals from the electrodes. [0037] Typically, the system 10 includes other elements, which are not shown in the figures for the sake of simplicity. For example, the system 10 may include an electrocardiogram (ECG) monitor, coupled to receive signals from one or more body surface electrodes, so as to provide an ECG synchronization signal to the console 24. As mentioned above, the system 10 typically also includes a reference position sensor, either on an externally-applied reference patch attached to the exterior of the subject's body, or on an internally-placed catheter, which is inserted into the heart 12 maintained in a fixed position relative to the heart 12. Conventional pumps and lines for circulating liquids through the catheter 14 for cooling the ablation site are provided. [0038] Embodiments of the present invention measure the phase of the impedance between the catheter electrode and the body-surface electrode. This phase shifts markedly with distance between the catheter electrode and the tissue over the range of about 1 - 2 mm, between contact and non-contact, due to the attendant change in the capacitance between the electrode and the tissue. It thus provides a sensitive measure of short-range distance and contact. [0039] Reference is now made to Fig. 2, which is a composite drawing illustrating phase relationships of currents passing through an electrode of the catheter 14 as it moves into contact with wall 37 of heart 12 (Fig. 1) in accordance with an embodiment of the invention. A reference electrode 39 is optionally provided for this purpose. The reference electrode 39 does not contact the wall 37. The electrodes are driven with a signal at a known frequency, which passes through the tissue and is received by the body surface 9 electrodes 30 (Fig. 1) or some other receiving electrode. Waveforms at the right side of Fig. 2 include, from top to bottom, a reference waveform 41 taken from the reference electrode 39, a pre-contact waveform 43 from the ablation electrode 32, taken when the ablation electrode 32 is out of contact with the wall 37, a contact waveform 45, taken when the ablation electrode 32 is in mechanical contact with the wall 37, and a post-ablation waveform 47, following completion of ablative therapy but while the ablation electrode 32 is still in contact with the wall 37. [0040] Phase shifts are indicated by displacement of vertical lines 49, 51 drawn through corresponding maxima of the pre-contact waveform 43 and the contact waveform 45. The phase shifts occur when the ablation electrode 32 is brought into contact with the wall 37. The inventors have discovered that phase measurement of this sort can be used not only to verify tissue contact, but also to check the progress of ablation: as the lesion is created and while the ablation electrode 32 maintains contact with the tissue, the phase of the impedance between the ablation electrode 32 and the tissue changes. Alternatively, the change in the phase between the ablation electrode 32 and the tissue can be determined by any of the other phase determination methods described in the above mentioned U.S. Patent Application Publication Nos. 2008/0288038 and 2008/0275465. The appearance of a waveform approximating post-ablation waveform 47 gives an indication that the tissue has been ablated. [0041] During the ablation, persistent contact between the ablation electrode 32 and the wall 37 may be confirmed using a position sensor in conjunction with the positioning processor 22 (Fig. 1), or by any of the other techniques described above for verifying physical electrode contact with the target tissue. [0042] It should be noted that the phase of the signal received from the reference electrode 39 does not change substantially as the tip electrode makes contact with the tissue. The reference electrode 39 may therefore be used as a basis for measuring the phase shift of the current passing through the ablation electrode 32 or another tip electrode (not shown). The ablator can operate while concurrently monitoring the phase shift, It is not necessary to interlace the two operations.
10 [0043] Reference is now made to Fig. 3, which is a flow chart of a method of tissue ablation in accordance with an embodiment of the invention. At initial step 53 a catheter, constructed in accordance with one of the above-described embodiments, is introduced into the heart, and an ablation electrode, together with its associated temperature sensor, positioned near a target site using the positioning system 26 (Fig. 1). [0044] Next, at step 55 a reading is taken to obtain the phase of a pre-contact waveform. This may be done by operating the ablation electrode 32 (Fig. 2) in a calibration mode. Optionally, the phase of the pre-contact waveform is related to a waveform read from a reference electrode. In either case, the results are memorized. [0045] Next at step 57, mechanical contact between the ablation electrode 32 and the wall 37 is verified, using any of the aforementioned methods. [0046] Next, at step 59 a baseline contact waveform is obtained and memorized. [0047] Next, at step 61, the ablation electrode is activated to ablate the target tissue. [0048] Next, at step 63, after an interval that may vary according to the lesion desired and the judgment of the operator, an intra-operative waveform is obtained and its phase angle with respect to the baseline contact waveform or the reference waveform ascertained. The phase angle of the intra-operative waveform and a calculated estimation of the degree of completion of the intended lesion may be displayed for the operator. When the rate of change of the phase angle approaches zero, it may be inferred that changes in the tissue are no longer occurring and that the ablation is essentially complete. [0049] Typically, the phase angle is determined every few seconds, e.g., every 2 5, seconds, depending on the stability of the measurement. [0050] The power requirement for obtaining phase angle readings is a less than 10 milliwatts if the ablator is idle. If the ablator is active then 5 - 50 watts is required. [0051] Control now proceeds to decision step 65, where it is determined if a termination criterion has been met. Termination criteria that may apply are, for example: 11 (1) an absence of change in the phase angle over a time interval; (2) a return of the phase angle of the intra-operative waveform to that of the pre-contact waveform; and (3) failure of the phase angle to shift more than a threshold amount, e.g., 50% in comparison to an intra-operative waveform obtained in a previous iteration of a loop including steps 61, 63. [0052] If a termination criterion has not been met at decision step 65, then control returns to step 61. Otherwise control proceeds to final step 67, where the procedure is terminated. [0053] It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and sub-combinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description. [0054] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. [0055] The reference to any prior art in this specification is not and should not be taken as an acknowledgement or any form of suggestion that the prior art forms part of the common general knowledge in Australia.
2. The apparatus according to caim 1 wherein the visual indication includes a progress of an ablation procedure using the ablator with respect to an intended lesion in the target tissue. 25 3. The apparatus according to daim1or claim 2, further including fourth circuitry for determining, from the intra-operative determinations, that a termination criterion has been satisfied 4, The apparatus according to claim 3, wherein making the intra 30 operative determinations includes a comparison with a pre-contat determination of the phase of the electrical current taken from the ablation electrode, and wherein the termination criterion indudes a difference 25352v 13 between one of the intra-operative determinations and the pre-contact deterrniation that is less than a predetermined value, & The apparatus according to claim 4, wherein the termination criterion 6 includes a failure of one of the intra-operative determinations to vary from a preceding one of the intra-operative determinations by more than a threshold value.
6. The apparatus according to any one of the preceding claims wherein 10 making the intra-operative determinations includes a comparison with respective phases of a reference waveform taken from a reference electrode that is spaced apart from the target tissue,
7. The apparatus according to any one of the preceding claims, wherein 15 the steps of making intra-operative determinations and applying a dosage of energy are performed concurrently. 8, The apparatus according to any one of the preceding claims wherein making a pre-contact determinaion is performed at a power of less than 10 20 miliwats.
9. The apparatus according to any one of the preceding claims, wherein making intra-operative determinations is performed at a power of 5-50 watts 2536280v2
AU2013200007A 2012-01-04 2013-01-02 Contact assessment based on phase measurement Active AU2013200007B2 (en)
AU2013200007A1 AU2013200007A1 (en) 2013-07-18
AU2013200007B2 true AU2013200007B2 (en) 2016-03-03
AU2013200007A Active AU2013200007B2 (en) 2012-01-04 2013-01-02 Contact assessment based on phase measurement